PALI Palisade Bio, Inc. Common Stock Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
16:08
Aug 26
Aug 26
Author compares street vs retail biotech top lists and notes RVMD approval with pricing.
Author compares street vs retail biotech top lists and notes RVMD approval with pricing expectations, but frames all names as observational research rather than personal positions.
LOW
17:25
Aug 10
Aug 10
Highlights past successful biotech valuation calls.
Author lists numerous biotech and pharma tickers as past successful valuation calls, offering no current directional view.
LOW
15:52
Jul 15
Jul 15
Leveraged junior mining bull market play
Palisades Goldcorp accumulated the largest public warrant book (1.7 billion warrants, 22 per share) during 2024-25 on favorable terms, providing massive upside leverage to a junior mining bull market with limited downside, and has already demonstrated 25x return potential on those warrants.
HIGH
14:06
Apr 13
Apr 13
Buy PALI to exploit a relative value inefficiency.
Buy PALI to exploit a relative value inefficiency, as competitors are gaining multiples of PALI's entire market cap based on inferior open-label clinical data.
MED
About PALI Analyst Coverage
Buzzberg tracks PALI (Palisade Bio, Inc. Common Stock) across 3 sources. 2 bullish vs 0 bearish calls from 3 analysts. Sentiment: predominantly bullish (50%). 4 total trade ideas tracked. Latest voices: seedy19tron, Collin Kettell, A May MD.